Psychosocial needs assessment among an underserved, ethnically diverse cancer patient population

Cancer ◽  
2007 ◽  
Vol 109 (S2) ◽  
pp. 446-454 ◽  
Author(s):  
Alyson B. Moadel ◽  
Carole Morgan ◽  
Janice Dutcher
Keyword(s):  
Cancer Patient ◽  
Needs Assessment ◽  
Patient Population ◽  
Ethnically Diverse ◽  
Psychosocial Needs

Seeking meaning and hope: self-reported spiritual and existential needs among an ethnically-diverse cancer patient population

1999 ◽  
Vol 8 (5) ◽  
pp. 378-385 ◽  
Author(s):  
Alyson Moadel ◽  
Carole Morgan ◽  
Anne Fatone ◽  
Jennifer Grennan ◽  
Jeanne Carter ◽  
...  
Keyword(s):  
Cancer Patient ◽  
Patient Population ◽  
Ethnically Diverse ◽  
Existential Needs

scholarly journals Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population

2021 ◽  
Vol 14 (3) ◽  
pp. 272
Author(s):  
Shelby Barnett ◽  
Julie Errington ◽  
Julieann Sludden ◽  
David Jamieson ◽  
Vianney Poinsignon ◽  
...  
Keyword(s):  
Cancer Patient ◽  
Childhood Cancer ◽  
Patient Population ◽  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Drug Clearance ◽  
Current Data ◽  
Population Pharmacokinetic ◽  
Older Children ◽  
Patient Groups

Infants and young children represent an important but much understudied childhood cancer patient population. The pharmacokinetics and pharmacogenetics of the widely used anticancer prodrug cyclophosphamide were investigated in children <2 years of age. Concentrations of cyclophosphamide and selected metabolites were determined in patients administered cyclophosphamide at doses ranging from 100–1500 mg/m2 (5–75 mg/kg), with various infusion times as determined by the standard treatment regimen that each patient was receiving. Polymorphisms in genes including CYP2B6 and CYP2C19 were investigated. Data generated for cyclophosphamide were analysed using a previously published population pharmacokinetic model. Cyclophosphamide pharmacokinetics was assessed in 111 samples obtained from 25 patients ranging from 4–23 months of age. The average cyclophosphamide clearance for the patients was 46.6 mL/min/m2 (ranging from 9.4–153 mL/min/m2), with marked inter-patient variability observed (CV 41%). No significant differences in cyclophosphamide clearance or exposure (AUC) were observed between patient groups as separated by age or body weight. However, marked differences in drug clearance and metabolism were noted between the current data in children <2 years of age and recently published results from a comparable study conducted by our group in older children, which reported significantly lower cyclophosphamide clearance values and metabolite exposures using the same population pharmacokinetic model for analysis. Whilst this study demonstrates no significant differences in cyclophosphamide clearance in patients <2 years, it highlights large differences in dosing protocols across tumour types. Furthermore, the study suggests marked differences in cyclophosphamide clearance in children less than two years of age as compared to older patients.

OA08.04 Validation of Scalable, Automated Data Extraction in an Advanced Lung Cancer Patient Population

2021 ◽  
Vol 16 (10) ◽  
pp. S861-S862
Author(s):  
M. Gauthier ◽  
J. Law ◽  
L. Le ◽  
J.J.n. Li ◽  
S. Zahir ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patient ◽  
Patient Population ◽  
Lung Cancer Patient ◽  
Data Extraction ◽  
Advanced Lung Cancer

scholarly journals Identification of Prion Disease-Related Somatic Mutations in the Prion Protein Gene (PRNP) in Cancer Patients

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1480 ◽  
Author(s):  
Yong-Chan Kim ◽  
Sae-Young Won ◽  
Byung-Hoon Jeong
Keyword(s):  
Cancer Patient ◽  
Cancer Patients ◽  
Prion Protein ◽  
Patient Population ◽  
Somatic Mutations ◽  
Protein Gene ◽  
Prion Diseases ◽  
Prnp Gene ◽  
Prion Protein Gene ◽  
Total Cancer

Prion diseases are caused by misfolded prion protein (PrPSc) and are accompanied by spongiform vacuolation of brain lesions. Approximately three centuries have passed since prion diseases were first discovered around the world; however, the exact role of certain factors affecting the causative agent of prion diseases is still debatable. In recent studies, somatic mutations were assumed to be cause of several diseases. Thus, we postulated that genetically unstable cancer tissue may cause somatic mutations in the prion protein gene (PRNP), which could trigger the onset of prion diseases. To identify somatic mutations in the PRNP gene in cancer tissues, we analyzed somatic mutations in the PRNP gene in cancer patients using the Cancer Genome Atlas (TCGA) database. In addition, to evaluate whether the somatic mutations in the PRNP gene in cancer patients had a damaging effect, we performed in silico analysis using PolyPhen-2, PANTHER, PROVEAN, and AMYCO. We identified a total of 48 somatic mutations in the PRNP gene, including 8 somatic mutations that are known pathogenic mutations of prion diseases. We identified significantly different distributions among the types of cancer, the mutation counts, and the ages of diagnosis between the total cancer patient population and cancer patients carrying somatic mutations in the PRNP gene. Strikingly, although invasive breast carcinoma and glioblastoma accounted for a high percentage of the total cancer patient population (9.9% and 5.4%, respectively), somatic mutations in the PRNP gene have not been identified in these two cancer types. We suggested the possibility that somatic mutations of the PRNP gene in glioblastoma can be masked by a diagnosis of prion disease. In addition, we found four aggregation-prone somatic mutations, these being L125F, E146Q, R151C, and K204N. To the best of our knowledge, this is the first specific analysis of the somatic mutations in the PRNP gene in cancer patients.

scholarly journals Cell-free DNA (cfDNA) landscape in ERBB2 (HER2)-amplified Asian cancer patient population

2018 ◽  
Vol 29 ◽  
pp. ix114-ix115
Author(s):  
J. Lee ◽  
A. Franovic ◽  
T.A. Rich ◽  
Y. Shiotsu ◽  
V.M. Raymond ◽  
...  
Keyword(s):  
Cancer Patient ◽  
Patient Population ◽  
Cell Free Dna ◽  
Free Dna
Sign in / Sign up

Export Citation Format

Share Document